Eytan Ruppin's Bio
Eytan Ruppin received his M.D. and Ph.D. (Computer Science) from Tel-Aviv University where he has served as a professor of Computer Science & Medicine since 1995, conducting computational multi-disciplinary research spanning a wide variety of topics, including neuroscience, machine learning and systems biology. He joined the University of Maryland in July 2014 as director of its center for bioinformatics and computational biology and moved to the NCI in January 2018 as chief of its newly established cancer data science branch (CDSL). His lab co-identified the first metabolic synthetic lethal (SL) drug target to treat cancer (Nature, 2011), was the first to identify metabolic SLs in cancer in a genome-wide manner (Molecular Systems Biology, 2011) and the first to infer cancer SLs by mining patients tumor data (Cell, 2014). More recently, his research has been focused on developing new computational approaches for SL/transcriptomics based precision oncology (Nat Comm 2018, MSB 2019, Cancer Cell 2019, NCB 2019, Science Advances 2020) and for immunotherapy (Nat Med 2018, Cell 2018, JAMA Onc 2019, Nat Cancer 2020). Eytan is a co-founder of a few startup companies involved in precision medicine and cancer drug discovery, including Metabomed, Medaware and Pangea Therapeutics and is a member of the editorial boards of EMBO Reports and Molecular Systems Biology.